Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02576275
Title A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

marginal zone B-cell lymphoma

follicular lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Bendamustine + Rituximab

Duvelisib

Age Groups: adult
Covered Countries USA


No variant requirements are available.